Levetiracetam for MCI and Parkinson cognitive impairment
MCI
Perplexity summary and references
Summary
Levetiracetam (LEV), an FDA-approved antiepileptic drug, has emerged as a promising therapeutic for mild cognitive impairment (MCI) through multiple mechanisms involving hippocampal hyperactivity normalization and direct modulation of amyloid-beta production.pmc.ncbi.nlm.nih+1
Early Johns Hopkins Work
The pioneering research at Johns Hopkins, led by Michela Gallagher and collaborators, identified hippocampal hyperactivity in the dentate gyrus (DG) and CA3 subregions as a biomarker of amnestic MCI (aMCI) related to Alzheimer’s disease. Their work demonstrated that low doses of levetiracetam (125 mg twice daily) significantly reduced this DG/CA3 hyperactivity and improved pattern separation performance—a specific type of episodic memory task—in aMCI participants. A 2012 preclinical study in PNAS showed that among multiple antiepileptic drugs tested, only LEV effectively suppressed aberrant network activity in hAPP mice, and chronic treatment reversed behavioral abnormalities, cognitive impairments, hippocampal circuit remodeling, and synaptic deficits.pmc.ncbi.nlm.nih+1
Recent Amyloid Findings
A groundbreaking study published in Science Translational Medicine on February 10, 2026, revealed the direct mechanism by which levetiracetam prevents amyloid-beta production. Researchers at Northwestern discovered that toxic amyloid-beta 42 (Aβ42) accumulates within synaptic vesicles, and LEV—through binding to synaptic vesicle glycoprotein 2A (SV2a)—reduces amyloidogenic processing of APP by modifying synaptic vesicle cycling and increasing APP cell surface expression, promoting nonamyloidogenic processing. Stable isotope labeling with mass spectrometry confirmed that LEV prevents Aβ42 production in vivo, and analysis of human clinical trial data showed that Alzheimer’s patients treated with levetiracetam experienced significant delays between dementia diagnosis and death.science+1
Clinical Trials and Current Status
The HOPE4MCI phase III clinical trial (NCT03486938) is an NIH-supported, FDA-registered study testing AGB101 (a slow-release formulation of levetiracetam) for aMCI related to Alzheimer’s disease, aiming to provide both symptomatic relief and disease-modifying effects. Multiple other trials are investigating LEV for various MCI populations, including Parkinson’s disease-related aMCI (NCT04643327), which applies the Hopkins approach to establish proof of concept for PD-aMCI treatment. Earlier pilot studies (NCT01044758) established the foundation by demonstrating that low-dose LEV reduces medial temporal lobe hyperactivity and improves memory function in aMCI patients.clinicaltrials+4
What is this analysis of human clinical trial data?
The statement about delays between dementia diagnosis and death comes from the Science Translational Medicine paper by Rao et al., published February 10, 2026. However, the full text of that article that I accessed did not include this specific clinical data analysis—it appears this information was part of the study but may be in supplementary materials or additional sections not captured in the abstract.[pmc.ncbi.nlm.nih]
Location in Source Materials
According to the Northwestern University press release covering this research, the clinical data analysis is described in a section titled “Mining existing human clinical data”. The researchers obtained clinical data from the National Alzheimer’s Coordinating Center and conducted a correlative analysis comparing Alzheimer’s patients who took levetiracetam versus those taking lorazepam or no/other antiepileptic drugs. They found that Alzheimer’s patients who took levetiracetam were associated with a significant delay from the diagnosis of cognitive decline to death compared to the control groups.[news.northwestern]
Details and Caveats
Additional reporting in Newsweek indicates that patients who received levetiracetam exhibited a longer duration between the onset of cognitive decline and death—averaging several additional years—though the effect size was described as modest. The researchers emphasized that this analysis was correlational rather than a controlled clinical trial, meaning it shows an association but cannot definitively prove causation. This retrospective analysis leveraged levetiracetam’s existing FDA approval and widespread use to examine real-world clinical outcomes in Alzheimer’s patients who happened to be prescribed the drug (often for seizures or epileptiform activity).newsweek+1
The primary research article reference is: Rao et al., “Levetiracetam prevents Aβ production through SV2a-dependent modulation of APP processing in Alzheimer’s disease models,” Science Translational Medicine (2026), with the clinical data analysis likely detailed in the full article or supplementary materials beyond what was accessible in the abstract.[pmc.ncbi.nlm.nih]
Parkinson dementia
Study registered in 2020, proof of concept
The NCT04643327 trial is investigating levetiracetam specifically for amnestic mild cognitive impairment in Parkinson’s disease (PD-aMCI), representing the first study of its kind to apply the hippocampal hyperactivity therapeutic approach from Alzheimer’s research to Parkinson’s-related cognitive decline.clinicaltrials+1
Study Design and Rationale
This proof-of-concept trial, registered in November 2020, applies the Johns Hopkins therapeutic approach to PD patients with memory-dominant cognitive impairment. The study is based on evidence that aMCI in Parkinson’s disease is associated with rapid progression toward dementia and that hippocampal DG/CA3 subfield hyperactivation during episodic memory tasks serves as a biomarker similar to what’s observed in Alzheimer’s-related aMCI. The trial involves 28 PD-aMCI participants undergoing a 12-week randomized, placebo-controlled, double-blind crossover design with 14-day treatment periods of 125 mg levetiracetam twice daily (the same low dose used in AD studies), separated by a 4-week washout period.pmc.ncbi.nlm.nih+1
Primary Outcomes and Methodology
The primary outcomes measure changes in episodic memory function using a pattern separation task and DG/CA3 hippocampal subfield functional activity assessed via high-resolution functional MRI after each treatment phase. Pattern separation—the ability to distinguish similar memories—is a specific type of episodic memory that critically depends on the DG/CA3 region and shows deficits in aMCI. The study also includes 28 PD participants without memory impairment (PD-nMI) and 28 healthy controls who undergo fMRI only to establish baseline DG/CA3 activity comparisons. Secondary outcomes include global cognition measures, PD severity ratings, and adverse events, while feasibility outcomes track recruitment, eligibility, screen failure, and completion rates to inform future larger trials.pubmed.ncbi.nlm.nih+1
Expected Impact
Based on the successful reduction of hippocampal hyperactivity and improvement in pattern separation performance seen in Alzheimer’s-related aMCI with low-dose levetiracetam, researchers hypothesize that the drug will normalize DG/CA3 overactivation in PD-aMCI participants and improve memory performance. The study aims to establish levetiracetam as an early therapeutic option to reduce dementia risk in Parkinson’s disease and provide a foundation for larger clinical trials, with power calculations indicating that 24 PD-aMCI participants would provide 80% power to detect clinically meaningful differences. This represents an important extension of the levetiracetam therapeutic strategy beyond Alzheimer’s disease to address cognitive decline in the Parkinson’s population.pmc.ncbi.nlm.nih+1
Azelastine to protect from Covid
Perplexity summary
Azelastine nasal spray, an over-the-counter antihistamine, showed promise in preventing SARS-CoV-2 infections in a phase 2 randomized controlled trial published in JAMA Internal Medicine on September 2, 2025. The study, known as CONTAIN and conducted in Germany from March 2023 to July 2024, tested its prophylactic potential in healthy vaccinated adults.immattersacp+2
Study Design
Researchers at Saarland University Hospital enrolled 450 healthy adults aged 18-65 (mean age 33 years, 66% women), randomizing 227 to azelastine 0.1% nasal spray (one puff per nostril three times daily for 56 days) and 223 to placebo. Nearly all (99%) participants had received at least three COVID-19 vaccinations (median 672 days prior). Participants self-tested for SARS-CoV-2 via rapid antigen twice weekly, with positives confirmed by PCR; symptomatic cases prompted increased dosing (five times daily for three days).chestphysician+2
Key Results
In the intention-to-treat analysis, PCR-confirmed SARS-CoV-2 infections occurred in 2.2% of the azelastine group (5/227) versus 6.7% in placebo (15/223), yielding an odds ratio of 0.31 (95% CI, 0.11-0.87; P=0.02)—a 69% relative risk reduction. Secondary outcomes included longer time to infection among positives (31.2 vs. 19.5 days), fewer symptomatic infections overall (21 vs. 49 participants), and lower rhinovirus incidence (1.8% vs. 6.3%). Adverse events were similar between groups, mainly mild bitter taste, nosebleeds, and tiredness; no serious treatment-related issues occurred.cidrap.umn+3
Limitations
The trial’s single-center design, small sample, low infection rates, and focus on healthy vaccinated individuals limit generalizability to high-risk or unvaccinated populations. Industry funding by URSAPHARM (which designed the study) raises potential bias concerns, and broader antiviral effects (e.g., on rhinovirus) require confirmation.dig.pharmacy.uic+1
Medical Commentary
Medical outlets like ACP Internist and CIDRAP highlighted the findings’ potential for scalable prophylaxis in high-exposure scenarios but stressed larger phase 3 trials in diverse groups. An accompanying JAMA editorial called for studies in severe COVID-19 risk populations. Reviews in Chest Physician and UIC Drug Information Group noted tolerability but urged multicenter validation due to design variability and lack of guideline endorsement. No phase 3 results were available as of January 2026.verahealth+4
Limitations and concerns
The authors of the CONTAIN trial explicitly acknowledged several limitations and potential sources of bias in their JAMA Internal Medicine paper:
Methodological Limitations
- Modest sample size: With only 450 participants total (227 azelastine, 223 placebo), the trial had limited statistical power and the low overall infection rates (20 total confirmed cases) may affect the reliability of the effect estimates[chestphysician]
- Single-center design: The entire study was conducted at Saarland University Hospital in Homburg, Germany, raising questions about whether findings would replicate across different clinical settings and geographic locations[chestphysician]
- Homogeneous study population: Participants were predominantly healthy (ages 18-65, mean 33 years), vaccinated (99% with ≥3 doses), and lacked diversity (93% White, 66% female), limiting generalizability to immunocompromised individuals, older adults, unvaccinated populations, or more ethnically diverse groups[chestphysician]
Potential Bias
- Unblinding risk from taste: The authors specifically noted that azelastine’s characteristic bitter taste “could have partially unblinded participants, potentially introducing bias” in self-reported outcomes or behavior
Unanswered Questions Raised by Authors
Dr. Bals and colleagues explicitly stated several areas requiring further investigation :
- Whether findings will replicate in multicenter cohorts with more diverse populations
- Efficacy in immunocompromised or elderly individuals
- Optimal dosing regimen and duration for real-world protection
- Whether azelastine provides protection against other respiratory pathogens beyond SARS-CoV-2 and rhinovirus
The authors emphasized that their results represent “a signal of efficacy that now warrants confirmation in larger phase 3 trials” rather than definitive proof of effectiveness .
Study sponsor and NO planned phase III studies!
URSAPHARM Arzneimittel GmbH is a German pharmaceutical company founded in 1974, headquartered in Saarbrücken, with a focus on ophthalmology, rhinology, and general practice products like eye drops, nasal sprays, and allergy treatments. It operates globally through subsidiaries in Europe, Russia, and India, plus partners in over 80 countries, employing over 950 people and specializing in manufacturing pharmaceuticals and medical devices.ursapharm+2
Role in Azelastine-COVID Research
URSAPHARM sponsored and manufactured the azelastine nasal spray for the CONTAIN phase 2 trial published in September 2025, partnering with researchers at Saarland University Hospital (near its HQ). The company previously collaborated with CEBINA on early COVID-19 repurposing efforts starting in 2020-2021.eurekalert+2
Phase 3 Trials Status
No phase 3 trials for azelastine nasal spray in SARS-CoV-2 prevention are currently recruiting, completed, or registered on ClinicalTrials.gov or EudraCT as of January 2026. Trial authors and commentaries consistently call for larger multicenter phase 3 studies to confirm efficacy in diverse populations, but none have been publicly announced or initiated by URSAPHARM or others. An earlier pilot trial (NCT06008860, completed 2023) tested Astepro (azelastine brand) for COVID management, not prevention.chestphysician+5
